BPC-157
Body Protection Compound-157 · GEPPPGKPADDAGLV · ~1419 Da
Executive Summary
BPC-157 is a 15-amino-acid synthetic peptide that has been studied mainly in animals and cell models for tissue repair, gastrointestinal protection, and broader organ protection effects. The preclinical literature contains many positive findings across many models, but this is not the same thing as "clinically proven", and the mechanistic story is still incomplete. Human evidence is thin and low quality: a retrospective chart review of knee injections (uncontrolled, subjective outcomes), a small pilot study for interstitial cystitis (12 participants, no control group), and a two-person pilot safety study of IV infusion. A Phase I oral safety/PK study (NCT02637284) was registered but no results are posted in the public record. From a regulatory standpoint, BPC-157 is not an approved human medicine; it is prohibited in sport under the S0 category by WADA, and the U.S. FDA explicitly raises safety concerns around immunogenicity risk, peptide impurities, and lack of safety information.
BPC-157 is preclinical-promising but clinically unproven; most confident online claims are ahead of human evidence; and safety/quality risks are not solved by enthusiasm.
What BPC-157 Is and What It Is Not
BPC-157 is described in the literature as a stable gastric pentadecapeptide, typically written as the amino-acid sequence GEPPPGKPADDAGLV (molecular weight ~1419). It is repeatedly framed as originating from fragments identified in gastric juice research, and was developed in the context of gastrointestinal cytoprotection ideas (protecting mucosa and then extending that concept to other tissues).
- It is not an approved therapeutic drug for any indication by major regulators, and should not be written about as if it were a standard-of-care regenerative medicine.
- It is not supported by published randomised controlled trials (RCTs) in humans for common internet uses (tendon tears, muscle strains, gut repair, neuroprotection).
- It is not "clearly safe" in the way people casually claim, because publicly available human safety datasets are extremely small and regulators explicitly cite missing safety information plus manufacturing/characterisation concerns.
Mechanism of Action
Angiogenesis and endothelial/NO signalling
Clearest independent mechanistic supportA 2017 study reports pro-angiogenic effects associated with increased expression and internalisation of VEGFR2 and activation of VEGFR2-Akt-eNOS signalling, with angiogenesis assays and improved blood flow recovery in a rat hind-limb ischaemia model. A 2020 paper reports that BPC-157 modulates vasomotor tone in isolated aorta in a concentration- and nitric-oxide-dependent manner, and suggests NO generation via a Src-caveolin-1-eNOS pathway.
These pathways are plausible contributors to healing-adjacent biology (blood flow, endothelial function), but do not equal proven clinical repair in humans.
Tendon-cell and fibroblast biology
Suggestive, not dispositiveA cell study in tendon fibroblasts reports that BPC-157 up-regulates growth hormone receptor expression (dose- and time-dependent), and that growth hormone then increases proliferation signals with downstream JAK2 activation.
This belongs in a mechanistic leads box: it supports possible effects on cell proliferation signalling, but it is still several steps away from human tendon outcomes.
Multiple proposed pathways
Claim, not resolved mechanismReviews describe interactions across neurotransmitters and the gut-brain axis, and repeatedly emphasise stability in gastric juice and broad system effects. These are hypothesis-generating narratives, not clinical proof, and they often synthesise many animal models without resolving bias, replication, or real-world dosing comparability.
BPC-157 has multiple proposed pathways (angiogenesis/NO, inflammatory signalling, cell migration), but "multiple pathways" can also mean "mechanism not pinned down yet."
Animal Evidence Map
The preclinical literature contains many positive findings, summarised below with stated limitations.
| Domain | Species | Dose | Outcome | Limitation |
|---|---|---|---|---|
| Achilles tendon transection | Rat | Not detailed in early paper | Improved Achilles tendon healing and in-vitro tendocyte stimulation | Rodent tendon healing; does not establish effect size or reliability in human tendon pathology. |
| MCL transection | Rat | 10 ug/kg or 10 ng/kg i.p. daily; topical 1.0 ug/g cream; oral 0.16 ug/mL water | Multiple routes effective for ligament healing outcomes | Single species, surgically created injury, controlled environment; positive preclinical result does not inform human dosing, safety, or comparative effectiveness. |
| Quadriceps muscle transection | Rat | 10 ug/kg, 10 ng/kg, 10 pg/kg i.p. | Improved biomechanical load-to-failure, functional recovery, histological regeneration over 72 days | Dramatic results in rodents can be real and still fail to translate, especially when human injury types, rehabilitation forces, and comorbidities differ. |
| Colocutaneous fistula | Rat | 10 ug/kg or 10 ng/kg oral water or i.p. | Accelerated closure and improved functional leakage outcomes; NO-system interaction tested | Fistula models are far from the everyday leaky gut claim; repair in rats does not validate oral self-use or predict long-term human safety. |
| Neuroleptic gastric injury + catalepsy | Mouse/Rat | 10 ug/kg or 10 ng/kg i.p. | Attenuated neuroleptic-induced catalepsy and inhibited haloperidol-associated gastric lesions | These are pharmacology models; they support biological activity, not broad clinical claims like heals the gut lining in humans. |
| Systemic organ protection (I/R injury) | Rat | Standard research doses | Examined distant-organ injury (kidney/liver/lung) following skeletal muscle ischaemia-reperfusion | Systemic I/R models are complex; generalising them to human wellness claims is a major leap without controlled human clinical work. |
Human Evidence
Every published human study for BPC-157 is reviewed below. None are randomised controlled trials.
Retrospective knee pain injection study
Uncontrolled retrospective chart reviewSubjective outcomes, only minority had pre-procedure MRI, no randomisation, no control group, heterogeneous diagnoses, high risk of placebo effects and selection bias.
Hypothesis-generating at best. Cannot establish efficacy.Interstitial cystitis pilot
Single-site pilot, no control groupSmall sample, lack of sham control. The limitations section of the paper itself explicitly notes these issues.
Signal is interesting but this is not clinical validation; needs independent replication with blinded outcomes.IV infusion safety pilot
Pilot safety studyn=2 can only support a narrow statement. Cannot establish general safety, rare adverse events, long-term risks, or safety of non-IV routes.
No obvious acute toxicity in two people under those conditions. Not a safety database.Phase I oral safety/PK trial
Registered Phase I RCT (NCT02637284)A registered trial without public results is evidence of investigation, not evidence of efficacy or safety.
Evidence of investigation only. No posted results.Hype vs Evidence
Common online claims compared against what the published evidence actually supports.
| Claim | Social Media Implies | Evidence Supports | Verdict |
|---|---|---|---|
| Heals tendon tears / ligament ruptures fast | Direct repair of human tears; faster return to sport | Multiple rodent surgical injury models show improved healing at ng/kg-ug/kg dosing; human evidence limited to uncontrolled knee pain chart review (not tendon tears per se); registered hamstring strain trial exists but no outcomes yet. |
Preclinical-promising; clinically unproven
|
| Fixes knee pain and builds cartilage | Regenerates cartilage; avoids surgery | One uncontrolled retrospective injection study reports symptom improvement, but no control group, limited imaging, and subjective endpoints prevent efficacy conclusions. |
Not proven; high bias risk
|
| Heals the gut / leaky gut | Reliable human GI repair from oral dosing | Rat GI models (fistula healing, ulcer protection) show biological activity; human ulcerative colitis work referenced historically but public trial results not visible as full peer-reviewed clinical paper. |
Animal evidence exists; human proof missing
|
| Neuroprotective / dopamine / brain repair | Cognitive enhancement; treatment for neurological disease | Animal pharmacology signals exist (catalepsy attenuation; CNS-focused reviews), but there is no robust human neurological outcomes dataset. |
Speculative in humans
|
| Completely safe / no side effects | Safe enough for self-injection | Regulators explicitly cite insufficient safety information and immunogenicity/impurity concerns; human datasets are tiny (n=2 IV safety). |
Unsupported; safety is uncertain
|
| Legal and standard in clinics | Treated like routine peptide therapy | WADA prohibits; FDA flags compounding risk; anti-doping bodies warn of non-approved status and unknown dosing. |
Regulatory risk is real
|
Evidence Strength Ratings
Each domain rated on a 0-5 scale based on quality and quantity of available evidence.
Safety, Side Effects & Regulatory Status
Prototype BPC-157 showed short elimination half-life (<30 minutes) in rats and beagle dogs after IV and IM dosing, with rapid Tmax (~9 minutes) after IM injections; IM bioavailability ~14-19% in rats and ~45-51% in dogs. Using radiolabelled BPC-157, total radioactivity suggested extensive metabolism/decomposition; urinary excretion dominant, with higher levels later in kidney and liver. The "it's stable in the stomach so it must work orally" story is incomplete: stability and bioavailability are not the same, and animal PK does not substitute for human PK.
The human clinical literature is too small to establish safety: the knee pain chart review, the interstitial cystitis pilot, and the IV n=2 study are not a safety database. Animal studies and reviews often assert wide safety margins, but the highest-integrity approach is to anchor safety claims to actual regulatory statements.
Explicitly cites potential safety risks: immunogenicity concerns for certain routes, peptide-related impurities, complexity of API characterisation, and insufficient information to know whether it would cause harm when administered to humans.
View Official Source →Named as an example under S0 on the 2026 Prohibited List (valid 1 January 2026). Added by name in 2022 after re-evaluation.
View Official Source →Emphasises BPC-157 is prohibited and not approved for human clinical use; safe dosing is unknown because it has not been extensively studied in humans.
View Official Source →Describes BPC-157 as an unapproved drug; safety/effectiveness have not been thoroughly evaluated in humans.
View Official Source →What We Still Don't Know
- No published human RCTs for tendon/ligament/muscle healing outcomes.
- No robust human pharmacokinetics by route (oral vs subcutaneous vs intra-articular), and animal PK does not solve this.
- No credible long-term safety database; rare harms cannot be ruled out from n=2 or n=12 studies.
- No manufacturing-quality reassurance in grey markets; FDA explicitly flags peptide impurity/characterisation complexities and limited safety information.
- Mechanism remains incomplete: endothelial/angiogenic signalling is plausible, but a unifying target that predicts who benefits, who doesn't, and who is harmed is not established.
References
All primary sources cited in this review. Links open in new tabs.
-
BPC-157 Achilles tendon transection healingEarly paper describing improved Achilles tendon healing and in-vitro tendocyte stimulation in rats
-
MCL transection ligament healing with multiple routesRat MCL healing with i.p., topical, and oral administration routes
-
Colocutaneous fistula healing with NO-system interactionRat fistula closure with BPC-157 at 10 ug/kg and 10 ng/kg; NO-system interaction tested
-
Quadriceps transection healing across dose rangesRat muscle healing at 10 ug/kg, 10 ng/kg, 10 pg/kg i.p. over 72 days
-
Neuroleptic catalepsy attenuation and gastric ulcer protectionBPC-157 attenuated neuroleptic-induced catalepsy and inhibited haloperidol-associated gastric lesions in mice/rats
-
Growth hormone receptor up-regulation in tendon fibroblastsCell study showing BPC-157 up-regulates GHR expression with downstream JAK2 activation
-
Pro-angiogenic mechanism via VEGFR2-Akt-eNOS pathwayDemonstrated VEGFR2-Akt-eNOS signalling and improved blood flow recovery in rat hind-limb ischaemia
-
Vasomotor tone and Src-Cav-1-eNOS signallingBPC-157 modulates vasomotor tone in isolated aorta via Src-caveolin-1-eNOS pathway
-
PK/ADME in rats and dogsPharmacokinetics, biodistribution, and metabolism study including radiolabel distribution and IM bioavailability
-
Intra-articular injection for multiple types of knee painRetrospective chart review of 16 patients with intra-articular BPC-157 injections
-
Intravesical BPC-157 for interstitial cystitis pilotPilot study of 12 women with IC; intravesical injection totaling 10 mg
-
IV infusion safety pilot (n=2)IV infusion up to 20 mg in 2 healthy adults; no adverse effects reported
-
Phase I oral safety/PK trial (NCT02637284)Registered Phase I RCT for oral BPC-157 tablets; unknown status, no posted results
-
Systematic review: orthopaedic sports medicine perspectiveSystematic review noting limited clinical evidence for BPC-157 in orthopaedic applications
View the compound profile for BPC-157 including dosage forms, administration routes, and category information.
View Compound Profile →Frequently Asked Questions About BPC-157
BPC-157 shows promising results in animal studies for tissue repair, gastrointestinal protection, and organ protection. However, human clinical evidence is extremely limited. No published randomised controlled trials exist for common claims like tendon repair, gut healing, or neuroprotection. The overall evidence score is 2.5 out of 5.
Safety is uncertain. The human safety database is extremely small (studies with only 2–16 participants). The U.S. FDA explicitly cites potential safety risks including immunogenicity concerns and peptide impurities. It is prohibited in sport by WADA under the S0 category.
Due to the very small number of human studies, a comprehensive side effect profile has not been established. The limited studies report no obvious acute toxicity, but regulatory agencies warn about immunogenicity risk, peptide-related impurities, and insufficient safety information to determine whether it would cause harm.
Multiple rodent studies show improved tendon and ligament healing outcomes. However, human evidence is limited to one uncontrolled retrospective chart review of knee injections (16 patients, no control group). No published human RCTs exist for tendon or ligament healing.
BPC-157 is not an approved human medicine by any major regulator. It is explicitly prohibited in sport by WADA under S0 (Non-Approved Substances). The U.S. FDA classifies it as a Category 2 bulk drug substance with cited safety concerns. Legal status varies by jurisdiction.
Rat gastrointestinal models show biological activity for fistula healing and ulcer protection. However, human clinical proof of gut healing is missing. No peer-reviewed clinical trial results demonstrate GI repair efficacy in humans from oral dosing.
The clearest mechanistic evidence involves pro-angiogenic effects through VEGFR2-Akt-eNOS signalling, promoting blood vessel formation and blood flow. Additional proposed pathways include tendon fibroblast stimulation and inflammatory signalling modulation, but a unifying mechanism is not yet established.
Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026